Entera Bio Ltd. (ENTX) vs Spruce Biosciences, Inc. (SPRB)
A side-by-side comparison of Entera Bio Ltd. and Spruce Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ENTX
Entera Bio Ltd.
$2.57HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
SPRB
Spruce Biosciences, Inc.
$43.30HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — ENTX vs SPRB
growth of $100 · dividends reinvested · last 6yENTX +127.8% (+14.7%/yr)SPRB -96.4% (-42.6%/yr)ENTX compounded faster over this window
Log scale — wide-divergence pair
ENTX SPRB
ENTX vs SPRB: by the numbers
- •ENTX is the larger company ($126M vs $119M market cap).
- •Both run net losses; SPRB's is the smaller (0.00% vs -27235.71% net margin).
Metrics side by side
Valuation
| Metric | ENTX | SPRB |
|---|---|---|
| P/B ratio | 17.40 | 1.42 |
Profitability
| Metric | ENTX | SPRB |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | -27450.00% | 0.00% |
| Net margin | -27235.71% | 0.00% |
| ROE | -234.42% | -61.33% |
| ROIC | -82.87% | -50.67% |
Growth (annualized)
| Metric | ENTX | SPRB |
|---|---|---|
| Total return CAGR (5Y) | -10.57% | -36.23% |
Frequently asked
- How have ENTX and SPRB total returns compared?
- Over the past 5 years, ENTX delivered -10.57% and SPRB delivered -36.23% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.